Abstract
The function of many endogenous molecules in all eukaryotic cells depends on their subcellular localisation, being active when localized in one cellular compartment and inactive in another. Translocation or re-localization of mislocalized components in the optimal subcellular site may contribute to the development of novel cancer therapies and to the re-evaluation of conventional treatment. For instance, various agents are able to entrap cytoplasmic anti-apoptotic pathways to the nucleus, thus activating apoptosis. Moreover, amongst the factors identified so far, the optimal location of the tumor suppressor p53 for promoting cell arrest and apoptosis seems to be the nucleus, while the nuclear factor kappa B (NFκB) is desirable to stay in the cytoplasm. Thus, the mechanisms of nuclear translocation of endogenous signaling components, like p53, NFκB and various heat shock proteins (HSPs), may serve as targets for pharmacological intervention, without excluding the possible role of uptake and active transport into the nucleus of extracellular proteins.
Keywords: Anticancer agents, cell cycle, nuclear translocation, stress response, yeast
Current Medicinal Chemistry
Title: Nuclear Translocation During the Cross-Talk Between Cellular Stress, Cell Cycle and Anticancer Agents
Volume: 13 Issue: 11
Author(s): E. Tiligada
Affiliation:
Keywords: Anticancer agents, cell cycle, nuclear translocation, stress response, yeast
Abstract: The function of many endogenous molecules in all eukaryotic cells depends on their subcellular localisation, being active when localized in one cellular compartment and inactive in another. Translocation or re-localization of mislocalized components in the optimal subcellular site may contribute to the development of novel cancer therapies and to the re-evaluation of conventional treatment. For instance, various agents are able to entrap cytoplasmic anti-apoptotic pathways to the nucleus, thus activating apoptosis. Moreover, amongst the factors identified so far, the optimal location of the tumor suppressor p53 for promoting cell arrest and apoptosis seems to be the nucleus, while the nuclear factor kappa B (NFκB) is desirable to stay in the cytoplasm. Thus, the mechanisms of nuclear translocation of endogenous signaling components, like p53, NFκB and various heat shock proteins (HSPs), may serve as targets for pharmacological intervention, without excluding the possible role of uptake and active transport into the nucleus of extracellular proteins.
Export Options
About this article
Cite this article as:
Tiligada E., Nuclear Translocation During the Cross-Talk Between Cellular Stress, Cell Cycle and Anticancer Agents, Current Medicinal Chemistry 2006; 13 (11) . https://dx.doi.org/10.2174/092986706776872952
DOI https://dx.doi.org/10.2174/092986706776872952 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interfacial Fast Release Layer in Monodisperse Poly (lactic-co-glycolic acid) Microspheres Accelerates the Drug Release
Current Drug Delivery Ceramide in Chemotherapy of Tumors
Recent Patents on Anti-Cancer Drug Discovery Evaluation of Adhesion Force and Binding Affinity of Phytohemagglutinin Erythroagglutinating to EGF Receptor on Human Lung Cancer Cells
Current Medicinal Chemistry Advances in High-Field Magnetic Resonance Spectroscopy in Alzheimer’s Disease
Current Alzheimer Research A Review of Cationic Arylfurans and Their Isosteres: Synthesis and Biological Importance
Current Organic Chemistry Target Recognition Molecules and Molecular Modeling Studies
Current Topics in Medicinal Chemistry New Insights on the Perturbations of T Cell Cycle During HIV Infection
Current Medicinal Chemistry Star Shaped Poly(ethylene glycols) Yield Biocompatible Gene Delivery Systems
Pharmaceutical Nanotechnology Patent Selections :
Recent Patents on Biomarkers 6-Membered Pyrrololactams: An Overview of Current Synthetic Approaches to their Preparation
Current Organic Chemistry Lutetium-177 Labeled Bombesin Peptides for Radionuclide Therapy
Current Radiopharmaceuticals Sensing, Transport and Other Potential Biomedical Applications of Pseudopeptides
Current Medicinal Chemistry Editorial [(Drugs and the Upper and Lower Gastrointestinal Tract: From Inflammation To Malignancy)
Current Drug Metabolism Extraction, Structure and Bioactivities of the Polysaccharides from Fructus corni
Recent Patents on Food, Nutrition & Agriculture Integrated Analysis of mRNA-seq and miRNA-seq to Identify c-MYC, YAP1 and miR-3960 as Major Players in the Anticancer Effects of Caffeic Acid Phenethyl Ester in Human Small Cell Lung Cancer Cell Line
Current Gene Therapy Radiolabeled Peptides for Molecular Imaging of Apoptosis
Current Medicinal Chemistry Novel Therapeutic Potential of Mitogen-Activated Protein Kinase Activated Protein Kinase 2 (MK2) in Chronic Airway Inflammatory Disorders
Current Drug Targets Biological Drugs in Guillain-Barré Syndrome: An Update
Current Neuropharmacology Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA Plant Polyphenols and Oral Health: Old Phytochemicals for New Fields
Current Medicinal Chemistry